{'52WeekChange': 0.9897399,
 'SandP52WeekChange': 0.0644362,
 'address1': '777 Old Saw Mill River Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 614.99,
 'askSize': 900,
 'averageDailyVolume10Day': 673975,
 'averageVolume': 1323844,
 'averageVolume10days': 673975,
 'beta': 0.571428,
 'beta3Year': None,
 'bid': 600,
 'bidSize': 2200,
 'bookValue': 109.277,
 'category': None,
 'circulatingSupply': None,
 'city': 'Tarrytown',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 623.7,
 'dayLow': 596.1,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': 0.355,
 'enterpriseToEbitda': 24.072,
 'enterpriseToRevenue': 7.756,
 'enterpriseValue': 64523661312,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 619.95087,
 'fiftyTwoWeekHigh': 664.64,
 'fiftyTwoWeekLow': 271.37,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 106168869,
 'forwardEps': 32.57,
 'forwardPE': 18.696346,
 'fromCurrency': None,
 'fullTimeEmployees': 8030,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.23819,
 'heldPercentInstitutions': 0.68354,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/regeneron.com',
 'longBusinessSummary': 'Regeneron Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, discovers, invents, develops, manufactures, '
                        'and commercializes medicines for treating various '
                        "medical conditions worldwide. The company's products "
                        'include EYLEA injection to treat wet age-related '
                        'macular degeneration and diabetic macular edema '
                        '(DME); myopic choroidal neovascularization; and '
                        'diabetic retinopathy in patients with DME, as well as '
                        'macular edema following retinal vein occlusion, '
                        'including macular edema following central retinal '
                        'vein occlusion and macular edema following branch '
                        'retinal vein occlusion. It also provides Dupixent '
                        'injection to treat atopic dermatitis in adults, and '
                        'asthma in adults and adolescents; Praluent injection '
                        'for heterozygous familial hypercholesterolemia or '
                        'clinical atherosclerotic cardiovascular disease in '
                        'adults; and Kevzara solution for subcutaneous '
                        'injection for treating rheumatoid arthritis in '
                        'adults. In addition, the company offers Libtayo '
                        'injection to treat metastatic or locally advanced '
                        'cutaneous squamous cell carcinoma; ARCALYST injection '
                        'for cryopyrin-associated periodic syndromes, '
                        'including familial cold auto-inflammatory syndrome '
                        'and muckle-wells syndrome; and ZALTRAP injection for '
                        'intravenous infusion to treat metastatic colorectal '
                        'cancer. Further, it is developing various product '
                        'candidates for treating patients with eye diseases, '
                        'allergic and inflammatory diseases, cancer, '
                        'cardiovascular and metabolic diseases, neuromuscular '
                        'diseases, infectious diseases, and other diseases. '
                        'The company has collaboration and license agreements '
                        'with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; '
                        'Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as '
                        'well as has an agreement with the U.S. Department of '
                        'Health and Human Services for the development of new '
                        'treatments combating the coronavirus. It also has a '
                        'collaboration with Zai Lab Limited and Intellia '
                        'Therapeutics, Inc. Regeneron Pharmaceuticals, Inc. '
                        'was founded in 1988 and is headquartered in '
                        'Tarrytown, New York.',
 'longName': 'Regeneron Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 62474199040,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_33715',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 2279300096,
 'nextFiscalYearEnd': 1640908800,
 'open': 623.7,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 2.62,
 'phone': '914 847 7000',
 'previousClose': 630.31,
 'priceHint': 2,
 'priceToBook': 5.5724444,
 'priceToSalesTrailing12Months': 7.509821,
 'profitMargins': 0.27399,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 623.7,
 'regularMarketDayLow': 596.1,
 'regularMarketOpen': 623.7,
 'regularMarketPreviousClose': 630.31,
 'regularMarketPrice': 623.7,
 'regularMarketVolume': 1206380,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 100746000,
 'sharesPercentSharesOut': 0.0207,
 'sharesShort': 2122545,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1987257,
 'shortName': 'Regeneron Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0291,
 'shortRatio': 1.85,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'REGN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 19.91,
 'trailingPE': 30.584631,
 'twoHundredDayAverage': 510.5126,
 'volume': 1206380,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.regeneron.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10591'}